Mersana Therapeutics Inc. announced that the U.S. Food and Drug Administration lifted the partial clinical hold on the Phase 1 study of the experimental cancer drug XMT-1522.
A new report finds that taking antibiotics for a common bacteria, Helicobacter pylori, reduces the occurrence of gastric cancer. For decades, doctors have understood that H. pylori infection plays a role in malignancy of […]
